Objective: To compare the effects of a first-line therapy of combined arginine vasopressin, levosimendan, and norepinephrine with arginine vasopressin + norepinephrine or norepinephrine alone in ovine septic shock. Design: Prospective, randomized, controlled laboratory experiment. Setting: University animal research facility. Subjects: Twenty-one chronically instrumented sheep. Interventions: After the onset of fecal peritonitis-induced septic shock (mean arterial pressure <60 mm Hg), sheep were randomly assigned to receive first-line treatment with arginine vasopressin (0.5 mU.kg(-1).min(-1)), combined arginine vasopressin (0.5 mU.kg(-1).min(-1)) and levosimendan (0.2 mu g.kg(-1).min(-1)), or normal saline (each n = 7) for 24 hrs. In all groups, open-label norepinephrine was additionally titrated to maintain mean arterial pressure at 70 +/- 5 mm Hg, if necessary. Measurements and Main Results: Arginine vasopressin + levosimendan + norepinephrine improved left ventricular contractility (higher stroke work indices at similar or lower preload) and pulmonary function (Pao(2)/FIo(2) ratio) when compared with the other groups (p < .05 each). Both nonadrenergic treatment strategies reduced open-label norepinephrine doses. However, only arginine vasopressin + levosimendan + norepinephrine limited fluid requirements and positive fluid balance vs. both other groups (p < .05 each). In addition, arginine vasopressin + levosimendan + norepinephrine increased mixed venous oxygen saturation as compared with arginine vasopressin + norepinephrine. Histologic tissue analyses and pulmonary hemeoxygenase-1 activity revealed no differences among groups. Notably, arginine vasopressin + levosimendan + norepinephrine therapy reduced pulmonary 3-nitrotyrosine levels (p = .028 vs. control animals) as well as urinary protein/creatinine ratio (p < .05 each) and slightly prolonged survival when compared with both other groups (4 hrs vs. arginine vasopressin + norepinephrine: p = .013; 7 hrs vs. norepinephrine alone: p = .003). Conclusions: First-line cardiovascular support with combined arginine vasopressin and levosimendan supplemented with norepinephrine improves myocardial, vascular, pulmonary, and renal function as compared with arginine vasopressin + norepinephrine in septic shock
Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock / Rehberg, Sebastian; Ertmer, Christian; Vincent, Jean-L.; Spiegel, Hans-U.; Köhler, Gabriele; Erren, Michael; Lange, Matthias; Morelli, Andrea; Seisel, Jennifer; Su, Fuhong; Van Aken, Hugo; Traber, Daniel L.; Westphal, Martin. - In: CRITICAL CARE MEDICINE. - ISSN 0090-3493. - STAMPA. - 38:10(2010), pp. 2016-2023. [10.1097/CCM.0b013e3181ef4694]
Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock
Morelli, Andrea;
2010
Abstract
Objective: To compare the effects of a first-line therapy of combined arginine vasopressin, levosimendan, and norepinephrine with arginine vasopressin + norepinephrine or norepinephrine alone in ovine septic shock. Design: Prospective, randomized, controlled laboratory experiment. Setting: University animal research facility. Subjects: Twenty-one chronically instrumented sheep. Interventions: After the onset of fecal peritonitis-induced septic shock (mean arterial pressure <60 mm Hg), sheep were randomly assigned to receive first-line treatment with arginine vasopressin (0.5 mU.kg(-1).min(-1)), combined arginine vasopressin (0.5 mU.kg(-1).min(-1)) and levosimendan (0.2 mu g.kg(-1).min(-1)), or normal saline (each n = 7) for 24 hrs. In all groups, open-label norepinephrine was additionally titrated to maintain mean arterial pressure at 70 +/- 5 mm Hg, if necessary. Measurements and Main Results: Arginine vasopressin + levosimendan + norepinephrine improved left ventricular contractility (higher stroke work indices at similar or lower preload) and pulmonary function (Pao(2)/FIo(2) ratio) when compared with the other groups (p < .05 each). Both nonadrenergic treatment strategies reduced open-label norepinephrine doses. However, only arginine vasopressin + levosimendan + norepinephrine limited fluid requirements and positive fluid balance vs. both other groups (p < .05 each). In addition, arginine vasopressin + levosimendan + norepinephrine increased mixed venous oxygen saturation as compared with arginine vasopressin + norepinephrine. Histologic tissue analyses and pulmonary hemeoxygenase-1 activity revealed no differences among groups. Notably, arginine vasopressin + levosimendan + norepinephrine therapy reduced pulmonary 3-nitrotyrosine levels (p = .028 vs. control animals) as well as urinary protein/creatinine ratio (p < .05 each) and slightly prolonged survival when compared with both other groups (4 hrs vs. arginine vasopressin + norepinephrine: p = .013; 7 hrs vs. norepinephrine alone: p = .003). Conclusions: First-line cardiovascular support with combined arginine vasopressin and levosimendan supplemented with norepinephrine improves myocardial, vascular, pulmonary, and renal function as compared with arginine vasopressin + norepinephrine in septic shockI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
